At the Shareholders' Meeting held on 16 June 2016, the shareholders of Kuros Biosciences AG approved a reverse stock split at a ratio of 100 to 1. The last trading day of the old registered shares with a nominal value of CHF 0.01 on the SIX Swiss Exchange was 22 June 2016, the listing and first trading day of the new registered shares with a nominal value of CHF 1 was 23 June 2016. VISCHER acted as transaction counsel for Kuros Biosciences AG and Zürcher Kantonalbank (acting as lead manager). The team comprised Dr. Matthias Staehelin (Partner), Angelo Imperiale (Associate) both Corporate and Nadia Tarolli (Partner) Tax.